Nicholas Carter | arXiv Science

arXiv2026

Bandit Algorithms for Deep Brain Stimulation

Deep Brain Stimulation (DBS) is an effective treatment for Parkinson's disease, but conventional fixed-parameter stimulation can reduce battery life and cause side effects while failing to adapt to changing neural dynamics. Recent reinforcement learning approaches improve adaptability, yet most rely on deep neural networks that require offline training and are computationally too expensive for implantable hardware. This paper presents a resource-conscious adaptive DBS framework based on a Time- and Threshold-Triggered Pruned Multi-Armed Bandit (T3P MAB) algorithm. The proposed method jointly tunes stimulation frequency and amplitude, avoids prior training, and remains transparent enough to support clinician-guided adjustment. Using a computational basal ganglia-thalamic model, we show that T3P converges faster than competing MAB methods and outperforms deep-RL baselines in suppressing pathological beta-band activity while reducing stimulation power. We implemented it on different microcontrollers and report detailed energy measurements, showing convergence in under two minutes and suitability for resource-constrained implantable systems. These results support lightweight bandit-based control as a practical path toward personalized, energy-efficient DBS.

cs.LG↗

arXiv2025

In-Vivo Training for Deep Brain Stimulation

Deep Brain Stimulation (DBS) is a highly effective treatment for Parkinson's Disease (PD). Recent research uses reinforcement learning (RL) for DBS, with RL agents modulating the stimulation frequency and amplitude. But, these models rely on biomarkers that are not measurable in patients and are only present in brain-on-chip (BoC) simulations. In this work, we present an RL-based DBS approach that adapts these stimulation parameters according to brain activity measurable in vivo. Using a TD3 based RL agent trained on a model of the basal ganglia region of the brain, we see a greater suppression of biomarkers correlated with PD severity compared to modern clinical DBS implementations. Our agent outperforms the standard clinical approaches in suppressing PD biomarkers while relying on information that can be measured in a real world environment, thereby opening up the possibility of training personalized RL agents specific to individual patient needs.

cs.LG↗